Skip to content

Maximizing longevity and healthspan

Chronic diseases are becoming the greatest threat to global health – affecting billions of people, driving over 80% of healthcare costs, and placing unsustainable pressure on health systems.

New preventative health approaches are urgently required to reduce the global burden of complex chronic diseases. 

At PrecisionLife, we’ve identified a new class of actively protective drug targets – biological mechanisms that naturally defend against disease. These discoveries enable novel interventions to protect against disease and prevent disease progression.

This is the future of preventative healthcare and drug development. 

Actively protective biology drug targets

Helping people live longer, healthier lives

Increase healthspan

A key enabler for increasing the period of life spent in good health and reducing the global burden of chronic disease is finding cellular biology that resists disease pressures.

Biological protection

The PrecisionLife Combinatorial Analytics & AI platform is uniquely able to identify actively protective, disease resilient mechanisms across all chronic diseases.

Disease prevention

Actively protective biology offers new drug targets to develop prophylactic drugs and therapeutic vaccines that delay onset of symptoms and prevent disease progression.

Detecting mechanisms that prevent disease in high-risk individuals

Our platform identifies combinations of features that contribute to reducing risk of disease in individuals who remain healthy even though their genomic profile suggests that they have high risk of developing disease.

These protective signatures can be used to identify novel drug targets, pharmacogenomic and therapeutic mRNA opportunities, and to better stratify patients by overall disease risk and mechanistic subtype.

Identifying protected cohorts


We screen healthy populations against our risk models to find cohorts enriched in actively protective factors – subgroups that have the risk signatures which would normally result in disease, but have not been affected.

Finding protective signatures


By eliminating the disease associated risk genes we find the genes unique to the protected cohort, which appear to be protecting against the development of the disease, even in patients at high risk.

Selecting protective targets


We then conduct biological analyses to identify and characterize key genes, potential drug targets, genetic interactions, pathways, and mechanisms of action represented by the protective disease signatures.

Actively Protective Biology schematic-min

 

CASE STUDY

Actively protective biology in ALS

Amyotrophic lateral sclerosis (ALS) is a complex and fatal neurodegenerative disease with a strong genetic component.

Our ALS study discovered >30 risk-associated genes and 21 actively protective genes. These protective genes include GRIP1, which has previously been associated with rare cases of ALS reversal, and MTRR, which codes for an enzyme that is central to the role of vitamin B12 within the cell.

This observation supports findings from our causative analyses which found signal from three other genes linked with cobalamin/vitamin B12 uptake/transport – CUBN, LRP2 and CD320.

Vitamin B12/methylcobalamin has previously been explored in cellular, animal and clinical studies for its role in ALS, with promising outcomes and has now been approved for the treatment of ALS in Japan.

ALS actively protective biology-1-1

Identification of a replicated actively protective gene (MTRR) involved in uptake and function of cobalamin/vitamin B12 in ALS

PAPER

Actively Protective Combinatorial Analysis

A scalable new method for detecting variants that contribute to reduced disease prevalence in high-risk patients

Artificial Intelligence in the Life Sciences

 

 

Proactive, preventative healthcare

Our mechanostic tests and clinical decision support platform are transforming healthcare – identifying people who would benefit from specific interventions and enabling disease prevention – improving patient outcomes and reducing cost of care. 

Mechanostics®

Rapid, non-invasive tests to identify disease risk and guide therapy selection based on underlying disease mechanisms.

Clinical Decision Support

Interpretation of mechanostic tests with clinical reports that enable differential triage and early intervention.

Let's talk

Patients are counting on us

Be part of the future of disease prevention.
Partner with us to translate protective biology into breakthrough therapies.